_256_384.jpg)
News | February 26, 2021
Bayer delivers robust performance despite pandemic
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company will review FDA's response and decide on appropriate next steps soon.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
India business grew 11.8% YoY vs mid-single digit industry growth.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The centralized marketing authorization granted by the EC is valid in all EU Member
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Subscribe To Our Newsletter & Stay Updated
